A Systematic Review of the Role of Dysfunctional Wound Healing in the Pathogenesis and Treatment of Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disorder showcasing an interaction between genetic predisposition and environmental risks. This usually involves the coaction of a mixture of cell types associated with abnormal wound healing, leading to structural distortion and loss of gas exchange function. IPF bears fatal prognosis due to respiratory failure, revealing a median survival of approximately 2 to 3 years. This review showcases the ongoing progress in understanding the complex pathophysiology of IPF and it highlights the latest potential clinical treatments. In IPF, various components of the immune system, particularly clotting cascade and shortened telomeres, are highly involved in disease pathobiology and progression. This review also illustrates two US Food and Drug Administration (FDA)-approved drugs, nintedanib (OFEV, Boehringer Ingelheim, Ingelheim am Rhein, Germany) and pirfenidone (Esbriet, Roche, Basel, Switzerland), that slow IPF progression, but unfortunately neither drug can reverse the course of the disease. Although the mechanisms underlying IPF remain poorly understood, this review unveils the past and current advances that encourage the detection of new IPF pathogenic pathways and the development of effective treatment methods for the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gurtner, G. C., Werner, S., Barrandon, Y., & Longaker, M. T. (2008) · Nature · doi:10.1038/nature07039 · Cited by 6,542
Factors affecting wound healing
Guo, S., & DiPietro, L. A. (2010) · Journal of Dental Research · doi:10.1177/0022034509359125 · Cited by 5,792
Reactive Oxygen Species in Inflammation and Tissue Injury
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P., & Malik, A. B. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5149 · Cited by 4,897
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
(2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.2.ats01 · Cited by 4,196
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 3×
“Recently, the inflammatory process has been described as mild, consisting of a scanty interstitial infiltrate of lymphocytes and plasma cells, and is not considered as a critical factor related to IPF pathology [88].”
BackgroundInteractions between extracellular matrix and growth factors in wound healing
Schultz, G. S., & Wysocki, A. (2009) · Wound Repair and Regeneration · doi:10.1111/j.1524-475x.2009.00466.x · Cited by 1,126 · cited 2×
“Components of the ECM, mainly elastin and hyaluronan, are reported to express chemotactic activity on inflammatory cells, induce immune responses, and enhance adhesion of polymorphonuclear neutrophils (PMNs), and alter gene expression profiles in inflammatory cells [85].”
BackgroundFibroblasts in fibrosis: novel roles and mediators
Kendall, R. T., & Feghali-Bostwick, C. A. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00123 · Cited by 1,082
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“VEGF, FGF, and PDGF connect a number of processes including angiogenesis and fibrogenesis and have been implicated in the pathogenesis of IPF [66].”
BackgroundLoots, M. A. M., Lamme, E. N., Zeegelaar, J., Mekkes, J. R., Bos, J. D., & Middelkoop, E. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00381.x · Cited by 620
Neutrophils and Wound Repair: Positive Actions and Negative Reactions
Wilgus, T. A., Roy, S., & McDaniel, J. C. (2013) · Advances in Wound Care · doi:10.1089/wound.2012.0383 · Cited by 616 · cited 2×
“An important function of neutrophils is the clearance of cellular debris in the wound area, although these cells also produce substances such as reactive oxygen species (ROS), which cause some additional bystander damage [8,9].”
BackgroundEpidemiology of idiopathic pulmonary fibrosis
Ley, B., & Collard, H. (2013) · Clinical Epidemiology · doi:10.2147/clep.s54815 · Cited by 321 · cited 2×
“Table 1 outlines the prevalence and incidence estimates per 100,000 populations by geographic district [22,23].”
BackgroundTelomerase and idiopathic pulmonary fibrosis
Armanios, M. (2012) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2011.10.013 · Cited by 245 · cited 1×
“Shortening of the telomere is alarming for the cell as it causes DNA damage and promotes cell death [83].”
BackgroundLung Extracellular Matrix and Fibroblast Function
White, E. S. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201406-240mg · Cited by 231
Lehtonen, S. T., Veijola, A., Karvonen, H., Lappi-Blanco, E., Sormunen, R., Korpela, S., Zagai, U., Sköld, M. C., & Kaarteenaho, R. (2016) · Respiratory Research · doi:10.1186/s12931-016-0328-5 · Cited by 133 · cited 1×
“In addition, in both trials, patients in the nintedanib treatment arm were significantly more likely than patients in the placebo arm to be functionally stable at week 52 [68].”
ResultImpact of CLAD Phenotype on Survival After Lung Retransplantation: A Multicenter Study
Verleden, S. E., Todd, J. L., Sato, M., Palmer, S. M., Martinu, T., Pavlisko, E. N., Vos, R., Neyrinck, A., Van Raemdonck, D., Saito, T., et al. (2015) · American Journal of Transplantation · doi:10.1111/ajt.13281 · Cited by 123
Cited by
Idiopathic pulmonary fibrosis: pathogenesis and management
Sgalla, G., Iovene, B., Calvello, M., Ori, M., Varone, F., & Richeldi, L. (2018) · Respiratory Research · doi:10.1186/s12931-018-0730-2 · Cited by 573
Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis
Wang, J., Hu, K., Cai, X., Yang, B., He, Q., Wang, J., & Weng, Q. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.07.023 · Cited by 450
Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Mei, Q., Liu, Z., Zuo, H., Yang, Z., & Qu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797292 · Cited by 360
Immune dysregulation as a driver of idiopathic pulmonary fibrosis
Shenderov, K., Collins, S. L., Powell, J. D., & Horton, M. R. (2021) · Journal of Clinical Investigation · doi:10.1172/jci143226 · Cited by 295
Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin
Qin, L., Liu, N., Bao, C.-L.-M., Yang, D.-Z., Ma, G.-X., Yi, W.-H., Xiao, G.-Z., & Cao, H.-L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00952-0 · Cited by 114
“g TGF-β, PDGF, IL-1, TNF-α) and activate the related signaling pathways, leading to fibroblast proliferation, and differentiation [113].”
Background
Metadata
- Authors
- Betensley, A., Sharif, R., & Karamichos, D.
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2016-12-26
- Volume
- 6
- Issue
- 1
- Pages
- 2
- ISSN
- 2077-0383 (ISSN-L)
- OpenAlex
- W2567257918
- Cited by
- 119
- References
- 16
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.